Analyst Ratings For Arch Therapeutics (NASDAQ:ARTH)
Today, HC Wainwright reiterated its Buy rating on Arch Therapeutics (NASDAQ:ARTH) with a price target of $3.00.
There are 4 buy ratings on the stock.
The current consensus rating on Arch Therapeutics (NASDAQ:ARTH) is Buy (Score: 3.00) with a consensus target price of $2.83 per share, a potential 258.20% upside.
Some recent analyst ratings include
- 9/18/2017-HC Wainwright Reiterated Rating of Buy.
- 7/25/2017-Ifs Securities Reiterated Rating of Outperform.
- 2/13/2017-Rodman & Renshaw initiated coverage with a Buy rating.
Recent Trading Activity for Arch Therapeutics (NASDAQ:ARTH)
Shares of Arch Therapeutics closed the previous trading session at with shares trading hands.